Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Somatic PRDM2 c.4459delA mutations in colorectal cancers control histone methylation and tumor growth

ABSTRACT: Purpose: To identify the contribution of PRDM2 c.4459delA mutation to colorectal tumorigenesis Methods: We employed rAAV-mediated genome editing to correct somatic PRDM2 c.4459delA mutation in homozygously mutated cell line. Using next-generation sequencing we have compared transcriptional profile of parental and PRDM2-corrected cells. Results: RNA-seq profiling revealed that several hallmark cancer gene sets are affected by PRDM2 c.4459delA

ORGANISM(S): Homo sapiens

PROVIDER: GSE80033 | GEO | 2018/02/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Somatic <i>PRDM2</i> c.4467delA mutations in colorectal cancers control histone methylation and tumor growth.

Project description:The chromatin modifier PRDM2/RIZ1 is inactivated by mutation in several forms of cancer and is a putative tumor suppressor gene. Frameshift mutations in the C-terminal region of PRDM2, affecting (A)8 or (A)9 repeats within exon 8, are found in one third of colorectal cancers with microsatellite instability, but the contribution of these mutations to colorectal tumorigenesis is unknown. To model somatic mutations in microsatellite unstable tumors, we devised a general approach to perform genome editing while stabilizing the mutated nucleotide repeat. We then engineered isogenic cell systems where the PRDM2 c.4467delA mutation in human HCT116 colorectal cancer cells was corrected to wild-type by genome editing. Restored PRDM2 increased global histone 3 lysine 9 dimethylation and reduced migration, anchorage-independent growth and tumor growth in vivo. Gene set enrichment analysis revealed regulation of several hallmark cancer pathways, particularly of epithelial-to-mesenchymal transition (EMT), with VIM being the most significantly regulated gene. These observations provide direct evidence that PRDM2 c.4467delA is a driver mutation in colorectal cancer and confirms PRDM2 as a cancer gene, pointing to regulation of EMT as a central aspect of its tumor suppressive action.

| S-EPMC5716757 | biostudies-literature

Identification of targets genes of PRDM2 in G0 arrested myoblasts of C2C12

Project description:PRDM2 directly associates with the Myogenin promoter and repress its transcription. This led to the hypothesis that PRDM2 could potentially associate directly with other promoters and regulate their expression.To gain further insight into the pathways and genes controlled by PRDM2, ChIP-on-Chip analysis was performed using mouse 44K promoter array. Since PRDM2 represses transcription by H3K9 dimethylation, we were interested in determining which targets were occupied by PRDM2 as well as showed enrichment for H3K9me2. Hence ChIP-on-Chip analysis for H3K9me2 was performed to find the overlap between PRDM2 and H3K9me2 marked promoters.

2015-06-30 | GSE58748 | GEO

Transcriptional profiling of PRDM2 Knock down vs.controlGFPsh proliferating C2C12 Myoblasts

Project description:Knockdown of PRDM2 led to precocious differentiation. To understand the molecular basis for this phenotype, we performed microaary analysis of growing myoblasts. Genes differentially regulated by PRDM2 knock down were reveraled by microarray analysis using NIA15K mouse chips.

2015-06-30 | GSE58675 | GEO

Transcriptional profiling of PRDM2 Knock down vs.controlGFPsh differentiated C2C12 Myoblasts (D28hrs)

Project description:Knockdown of PRDM2 led to precocious differentiation. To understand the molecular basis for this phenotype, we performed microaary analysis of 28hr differentiated myoblasts. Genes differentially regulated by PRDM2 knock down were reveraled by microarray analysis using affymetrix mouse chips.

2015-06-30 | GSE58673 | GEO

Transcriptional profiling of PRDM2 Knock down vs.controlGFPsh Quiescent C2C12 Myoblasts (G0 enriched)

Project description:Knockdown of PRDM2 led to precocious differentiation. To understand the molecular basis for this phenotype, we performed microaary analysis of quiescent myoblasts. Genes differentially regulated by PRDM2 knock down were reveraled by microarray analysis using affymetrix mouse chips.

2015-06-30 | GSE58674 | GEO

Identification of targets genes of PRDM2 in G0 arrested myoblasts of C2C12

2015-06-30 | E-GEOD-58748 | biostudies-arrayexpress

Transcriptional profiling of PRDM2 Knock down vs.controlGFPsh proliferating C2C12 Myoblasts

2015-06-30 | E-GEOD-58675 | biostudies-arrayexpress

Transcriptional profiling of PRDM2 Knock down vs.controlGFPsh differentiated C2C12 Myoblasts (D28hrs)

2015-06-30 | E-GEOD-58673 | biostudies-arrayexpress

Transcriptional profiling of PRDM2 Knock down vs.controlGFPsh Quiescent C2C12 Myoblasts (G0 enriched)

2015-06-30 | E-GEOD-58674 | biostudies-arrayexpress

Somatic mutations in leukocytes infiltrating primary breast cancers.

Project description:BackgroundMalignant transformation requires the interaction of cancer cells with their microenvironment, including infiltrating leukocytes. However, somatic mutational studies have focused on alterations in cancer cells, assuming that the microenvironment is genetically normal. Because we hypothesized that this might not be a valid assumption, we performed exome sequencing and targeted sequencing to investigate for the presence of pathogenic mutations in tumor-associated leukocytes in breast cancers.MethodsWe used targeted sequencing and exome sequencing to evaluate the presence of mutations in sorted tumor-infiltrating CD45-positive cells from primary untreated breast cancers. We used high-depth sequencing to determine the presence/absence of the mutations we identified in breast cancer-infiltrating leukocytes in purified tumor cells and in circulating blood cells.ResultsCapture-based sequencing of 15 paired tumor-infiltrating leukocytes and matched germline DNA identified variants in known cancer genes in all 15 primary breast cancer patients in our cohort. We validated the presence of mutations identified by targeted sequencing in infiltrating leukocytes through orthogonal exome sequencing. Ten patients harbored alterations previously reported as somatically acquired variants, including in known leukemia genes (DNTM3A, TET2, and BCOR). One of the mutations observed in the tumor-infiltrating leukocytes was also detected in the circulating leukocytes of the same patients at a lower allele frequency than observed in the tumor-infiltrating cells.ConclusionsHere we show that somatic mutations, including mutations in known cancer genes, are present in the leukocytes infiltrating a subset of primary breast cancers. This observation allows for the possibility that the cancer cells interact with mutant infiltrating leukocytes, which has many potential clinical implications.

| S-EPMC5515194 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data